Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00179335 |
Recruitment Status
:
Completed
First Posted
: September 16, 2005
Last Update Posted
: August 6, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections | Procedure: Blood drawing to determine drug levels |
HIV infected patients, aged </= 35 years and aged >/= 55 years, who are regularly taking either efavirenz or lopinavir/ritonavir as part of their antiretroviral regimen are being asked to spend 12 hours at our clinic (the ACS clinic at Jacobi Medical Center, Bronx, NY) for an intensive pharmacokinetic study in which 5 cc of blood will be drawn 9 times over a 12 hour period. Patients taking EFV will return for one additional blood draw the following day.
Patients will be asked to come to the clinic at 7 am and bring their medication to the clinic. Blood will be drawn to obtain a trough level of either EFV or Lop/r after which the patient will be instructed to take their EFV or Lop/r. Then blood will be drawn 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours later. Patients on EFV will be asked to return the next morning for a 24 hour blood level.
The blood will be spun and the plasma frozen at - 70 C. The plasma samples, labelled with the patients' initials and the draw date, will be shipped to University of Alabama, Department of Pharmacology, where the drug levels will be measured.
Patients will be recruited from the ACS outpatient clinic. They will be identified by their providers.
Study Type : | Observational |
Actual Enrollment : | 45 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Cross Sectional Case-Sectional Control Pharmacokinetic Study of Efavirenz or Lopinavir/Ritonavir as Part of an Antiretroviral Regimen With Two Nucleosides in HIV-Infected Adults 55 Years of Age or Older Compared With Adults Aged 18-35 Years |
Study Start Date : | August 2003 |
Actual Primary Completion Date : | January 2006 |
Actual Study Completion Date : | September 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- HIV+
- Taking lopinavir/ritonavir or efavirenz
- Age </= 35 years or >/= 55 years
Exclusion Criteria:
- Concurrent therapy with drugs that alter lopinavir/ritonavir levels.
- Other renal or kidney disease.
- Chronic hepatitis B or C

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00179335
United States, New York | |
Jacobi Medical Center ACS Clinic | |
Bronx, New York, United States, 10461 |
Principal Investigator: | Elizabeth R Jenny-Avital, MD | Jacobi Medical Center, Albert Einstein College of Medicine | |
Principal Investigator: | Edward Acosta, Pharm D | University of Alabama at Birmingham |
Responsible Party: | Elizabeth Jenny-Avital, Jacobi Medical Center |
ClinicalTrials.gov Identifier: | NCT00179335 History of Changes |
Other Study ID Numbers: |
CCI 03 143 |
First Posted: | September 16, 2005 Key Record Dates |
Last Update Posted: | August 6, 2009 |
Last Verified: | August 2009 |
Keywords provided by Albert Einstein College of Medicine, Inc.:
Regular lopinavir/ritonavir or Efavirenz use Age >/= 55 y or </= 35 y HIV+ |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Efavirenz HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers |